We are on a mission to revolutionize the way sedative drugs are administered in the intensive care unit. This is a $2.4B market where there is a pressing demand to reduce costs (15% of a hospital’s budget and unprofitable) and to increase patient safety where medication errors lead to unnecessary mortality and morbidity. Our top team has developed a solution that is significantly better than the current standard of care with FDA 510(k) clearance, solid patent protection to 2023, and 10 years of clinical data through ten studies. Neuroscience and critical care thought leaders endorse and invest in our technology.
Ethicon Endo-Surgery Inc., a member of the Johnson & Johnson Family of Companies, has entered into a research collaboration and option agreement with BrainStem Biometrics Inc. through a deal facilitated by Johnson & Johnson Innovation. As part of the collaboration, Ethicon will co-fund studies to confirm the clinical and operational utility of BrainStem Biometrics’ Tremor Monitor Unit, a small, non-invasive medical device biosensor that is used to detect minute eye movements in patients undergoing anesthesia. As a likely marker of basic brainstem function, this technology has the potential to distinguish between safe and unsafe levels of sedation for patients around the world.